BioMarin Reports First Quarter 2026 Financial and Operating Results
BioMarin reported Q1 2026 total revenue of $766 million, up 3% year-over-year, with Non-GAAP diluted EPS of $0.76. The company significantly raised full-year 2026 revenue guidance to a range of $3.825 billion to $3.925 billion, reflecting a 20% growth rate at the midpoint driven by the addition of GALAFOLD and POMBILITI + OPFOLDA from the Amicus acquisition.
Key figures
- Eps
- 0.76
- Revenue
- $766 million
- Guidance
- FY26 Total Revenues $3.825B-$3.925B, raised from $3.325B-$3.425B; Non-GAAP EPS $4.85-$5.05, lowered from $4.95-$5.15
- Revenue Yoy
- 3%
- Debt financing
- $3.7 billion
- Operating cash flow
- $221 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.